Predicting Clinical Outcomes of SARS‐CoV‐2 Drug Efficacy with a High‐Throughput Human Airway Microphysiological System (Adv. Biology 11/2024)
SARS-CoV-2 Drug Efficacy Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.
Authors
- Elizabeth P. Gabriel (ORCID: https://orcid.org/0000-0003-4287-7006)
- Thomas J. Mulhern (ORCID: https://orcid.org/0000-0001-6437-6777)
- Jeffrey T. Borenstein (ORCID: https://orcid.org/0000-0002-4482-3274)
- Christine R. Fisher (ORCID: https://orcid.org/0000-0001-9308-9873)
- Rebeccah J. Luu (ORCID: https://orcid.org/0000-0003-4364-8985)
- Landys Lopez Quezada (ORCID: https://orcid.org/0000-0002-8789-4283)
- Felix Mba Medie (ORCID: https://orcid.org/0000-0002-8265-4563)
- Ashley L. Gard (ORCID: https://orcid.org/0000-0001-7436-469X)
- Robert B. Gaibler (ORCID: https://orcid.org/0000-0002-7492-683X)
- Logan D. Rubio
- Elizabeth E. Marr (ORCID: https://orcid.org/0000-0002-5507-634X)
Institutions
- Draper Laboratory (US)
Publication Details
- Journal
- Advanced Biology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/adbi.202470111
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.42